8-K: Orgenesis Inc. Faces OTCQX Delisting Threat Due to Delayed 10-K Filing

Orgenesis Inc. received a notice from OTCQX regarding non-compliance due to the delayed filing of its 2024 Form 10-K and has until June 2, 2025, to rectify the situation or face delisting.

Summary

• Orgenesis Inc. received a notice on April 17, 2025, indicating they are not in compliance with OTCQX requirements due to the late filing of their 2024 Form 10-K.
• The company has until June 2, 2025, to address this deficiency according to Section 4.1 (A) of the OTCQX Rules.
• Failure to file the 10-K by the deadline could result in removal from the OTCQX market.
• Orgenesis states they are dedicating significant resources to complete the Form 10-K.
• The company cites a focus on capital raising as a reason for the delay, requiring more time to complete the audit of their financial statements.
• There is no guarantee that Orgenesis will file the 10-K by June 2, 2025, and maintain its OTCQX listing.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the potential delisting from OTCQX and the delayed financial reporting, raising concerns about the company's financial health and compliance.

Negatives

• Orgenesis Inc. is non-compliant with OTCQX requirements due to the delayed filing of its 2024 Form 10-K.
• The company faces potential delisting from the OTCQX if the deficiency is not cured by June 2, 2025.

Risks

• The primary risk is the potential delisting from the OTCQX if the 2024 Form 10-K is not filed by June 2, 2025.
• There is no assurance that the company will meet the deadline, which could negatively impact investor confidence and stock value.

Future Outlook

The company's future on the OTCQX market is uncertain, contingent on their ability to file the 2024 Form 10-K by June 2, 2025.

Management Comments

• The Company has dedicated significant resources to completing the Form 10-K and is working diligently to complete the necessary work to file the 2024 Form 10-K as soon as practicable.
• The Company and its finance team have been focusing on capital raising and, therefore, requires more time to complete all the work required in order to file the Form 10-K including the completion of the audit of the Company's financial statements by the Company's independent auditors for inclusion in the 2024 Form 10-K.

Industry Context

Delays in financial reporting can erode investor confidence and raise concerns about a company's internal controls and financial health, potentially impacting its market valuation and access to capital.

Comparison to Industry Standards

• Timely filing of financial reports is a standard expectation for publicly traded companies.
• Companies like BioTime, Inc. (now Lineage Cell Therapeutics, Inc.) have faced similar delisting threats due to reporting delays, highlighting the importance of maintaining compliance with exchange requirements.
• Failure to meet these standards can lead to increased scrutiny from regulators and investors, as seen with companies like China Advanced Construction Materials Group, Inc., which faced SEC investigations for reporting deficiencies.

Stakeholder Impact

• Shareholders face the risk of decreased stock value and liquidity if the company is delisted.
• Employees may experience uncertainty due to the company's financial reporting issues.
• Creditors may reassess their risk exposure based on the company's compliance challenges.

Next Steps

• Orgenesis Inc. must file its 2024 Form 10-K by June 2, 2025, to maintain its OTCQX listing.

Key Dates

Keywords

OTCQX, Form 10-K, Delisting, Compliance, Orgenesis Inc., Filing Delay, Financial Reporting